BCL2L1 and B-cell chronic lymphocytic leukemia: These inhibitors are already FDA-approved for solid tumors and have been shown to reduce MCL-1 levels in CLL cells, and in the case of sunitinib also BCL-XL and BFL-1 levels [100, 101].